• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

    10/1/25 9:00:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care
    Get the next $SCNX alert in real time by email

    Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities

    U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension

    COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has formalized multiple commercial group purchasing organization (GPO) agreements for ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL, providing access to more than 2500 healthcare institutions, including hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers, representing potential penetration into an estimated 20% of the U.S. institutional market while also establishing a broad footprint across long-term care and outpatient facilities.

    "Securing these GPO agreements is a pivotal milestone for Scienture and for Arbli™," commented Narasimhan Mani, President and co-CEO of Scienture. "By gaining access to more than 2500 healthcare institutions, we are positioning Arbli™ to reach the patients and providers who need it most. Looking ahead, we plan to further expand our GPO partnerships and direct contracts to deepen institutional market penetration nationwide. This strategy underscores our commitment to creating meaningful growth opportunities and long-term value for shareholders."

    ArbliTM is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. ArbliTM is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. ArbliTM has two issued patents from the USPTO, which are also listed in the FDA Orangebook.

    According to IQVIA data (MAT June 2025), the U.S. losartan market represents approximately $256 million in annual sales and a prescription volume of 71 million (TRx), with all currently marketed products available only in oral solid form.

    "GPO agreements often serve as a strategic gateway," stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. "Once a product is listed on a contract, it becomes accessible to all member institutions, enabling adoption to scale rapidly without renegotiating individual agreements. These agreements highlight a significant opportunity for Arbli™ as the first FDA-approved, ready-to-use oral suspension."

    About ArbliTM

    ArbliTM is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.

    INDICATION

    ArbliTM is an angiotensin II receptor blocker (ARB) indicated for:

    • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
    • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
    • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.



    IMPORTANT SAFETY INFORMATION

    • Do not take ArbliTM when pregnant. When pregnancy is detected, discontinue ArbliTM as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ArbliTM can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.



    • Do not co-administer ArbliTM with aliskiren in patients with diabetes. Avoid use of aliskiren with ArbliTM in patients with renal impairment (GFR <60 mL/min).



    • Do not administer ArbliTM in patients with severe hepatic impairment. ArbliTM has not been studied in patients with severe hepatic impairment.



    • The most common adverse reactions are (incidence ≥2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.



    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.

    Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.

    About Hypertension

    Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.

    About Scienture Holdings, Inc.

    SCIENTURE HOLDINGS, INC. (NASDAQ: "SCNX"), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

    Cautionary Statements Regarding Forward-Looking Statements

    This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

    Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

    Contact:

    SCIENTURE HOLDINGS, INC.

    20 Austin Blvd

    Commack, NY 11725

    Phone: (866) 468-6535

    Email: [email protected]



    Primary Logo

    Get the next $SCNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

    Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli™ as the first FDA-approved ready-to-use oral suspension COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced

    10/1/25 9:00:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

    Arbli™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life COMMACK, NY, Sept. 16, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has formalized a major commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement

    9/16/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

    Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (NASDAQ:SCNX) ("Scienture" or the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $3.9 million bef

    8/14/25 9:00:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    SEC Filings

    View All

    Scienture Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    9/23/25 5:01:18 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form 424B5 filed by Scienture Holdings Inc.

    424B5 - Scienture Holdings, Inc. (0001382574) (Filer)

    9/19/25 5:15:16 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form EFFECT filed by Scienture Holdings Inc.

    EFFECT - Scienture Holdings, Inc. (0001382574) (Filer)

    8/28/25 12:15:25 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    Leadership Updates

    Live Leadership Updates

    View All

    SCIENTURE Announces Executive Leadership Transition

    TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

    5/22/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care